31.07.2013 • Newsgeneric drugsH1 resultsMerck

Pfizer, Merck Weather Weak Quarter

Big Pharma is still relying on belt-tightening to prop up financial results. Pfizer and Merck & Co said on Tuesday their quarterly results were again hit by generic competition for once top-selling products and the toll of a strong dollar on overseas revenue. Controls on marketing and administrative expenses, and other costs, helped them report earnings slightly above Wall Street estimates.

But neither company offered investors a quick return to growth based on new products, even if the worst of the patent cliff for best-selling drugs that have lost marketing exclusivity is behind them.

Merck said full-year sales were likely to be about 5 to 6% below last year's levels, even so, it stuck to its full-year profit outlook of $3.45 to $3.55 per share, excluding special items.

Pfizer, the largest U.S. drug maker, said second quarter revenue fell 7% to $12.97 billion, with 3% of the decline due to an unfavorable foreign exchange rate.

But Pfizer also trimmed costs and expenses by 3% and reiterated its full-year earnings forecast of $2.10 to $2.20 per share.

Pfizer said income, excluding special items, fell 10% to $4 billion, or 56 cents a share, from $4.45 billion, or 59 cents a share, a year earlier.

Merck earned $906 million, or 30 cents per share, down from $1.79 billion, or 58 cents per share, a year earlier. Excluding special items, Merck earned 84 cents a share.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.